It looks like FRX is going to be late to market with its LAMA/LABA combination. Not good for the commercial prospects insofar as FRX’s product does not seem well differentiated from the products offered by NVS and GSK/THRX.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”